CVR number 37933848
Industry 72.1100 Research and experimental development on biotechnology

Tubular Technologies ApS

 

Quicksearch
from your own companies
Analyst: XBRLDenmark
Loading...

Loading...

Loading...

Loading...

   
Loading...
Bankruptcy Risk 
2020
2020/7
2021
2021/7
2022
2022/7
2023
2023/7
2024
2024/7
Bankruptcy risk for industry  1.2% 1.2% 1.2% 1.2% 1.2%  
Bankruptcy risk  10.9% 12.2% 10.1% 12.8% 13.1%  
Credit score (0-100)  22 18 23 17 17  
Credit rating  BB BB BB BB BB  
Credit limit (kDKK)  0.0 0.0 0.0 0.0 0.0  
How are these values calculated?
 
View the automatically generated explanation of bankruptcy risk

Income statement (kDKK) 
2020
2020/7
2021
2021/7
2022
2022/7
2023
2023/7
2024
2024/7
Net sales  -4 -7 -6 -6 -8  
Gross profit  -3.9 -6.5 -6.4 -6.0 -7.8  
EBITDA  -3.9 -6.5 -6.4 -6.0 -7.8  
EBIT  -13.1 -13.5 -11.6 -9.9 -10.7  
Pre-tax profit (PTP)  -14.2 -14.2 -12.6 -11.5 -17.0  
Net earnings  -14.2 -14.2 -12.6 -11.5 -17.0  
Pre-tax profit without non-rec. items  -14.2 -14.2 -12.6 -11.5 -17.0  
 
See the entire income statement

Balance sheet (kDKK) 
2020
2020/7
2021
2021/7
2022
2022/7
2023
2023/7
2024
2024/7
Tangible assets total  27.7 20.8 15.6 11.7 8.8  
Shareholders equity total  71.7 57.6 45.0 33.5 17.0  
Interest-bearing liabilities  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  71.7 57.6 45.0 33.5 17.0  
Net Debt  -44.0 -36.8 -29.4 -21.8 -8.2  
 
See the entire balance sheet

Volume 
2020
2020/7
2021
2021/7
2022
2022/7
2023
2023/7
2024
2024/7
Net sales  -4 -7 -6 -6 -8  
Net sales growth  -51.8% 68.6% -2.0% -6.1% 28.9%  
Gross profit  -3.9 -6.5 -6.4 -6.0 -7.8  
Gross profit growth  51.8% -68.6% 2.0% 6.1% -28.9%  
Employees  0 0 0 0 0  
Employee growth %  0.0% 0.0% 0.0% 0.0% 0.0%  
Employee expenses  0.0 0.0 0.0 0.0 0.0  
Balance sheet total (assets)  72 58 45 34 17  
Balance sheet change%  -16.5% -19.7% -21.8% -25.5% -49.2%  
Added value  -3.9 -6.5 -6.4 -4.7 -7.8  
Added value %  100.0% 100.0% 100.0% 78.4% 100.0%  
Investments  -18 -14 -10 -8 -6  
Net sales trend  -1.0 1.0 -1.0 -2.0 1.0  
EBIT trend  -4.0 -5.0 -5.0 -5.0 -5.0  

Profitability 
2020
2020/7
2021
2021/7
2022
2022/7
2023
2023/7
2024
2024/7
EBITDA %  100.0% 100.0% 100.0% 100.0% 100.0%  
EBIT %  0.0% 0.0% 0.0% 0.0% 0.0%  
EBIT to gross profit (%)  338.2% 206.0% 181.1% 164.7% 137.7%  
Net Earnings %  364.6% 216.5% 195.9% 190.7% 218.8%  
Profit before depreciation and extraordinary items %  126.4% 110.5% 114.9% 126.0% 181.1%  
Pre tax profit less extraordinaries %  364.6% 216.5% 195.9% 190.7% 218.8%  
ROA %  -16.7% -20.9% -22.7% -25.3% -42.3%  
ROI %  -16.7% -20.9% -22.7% -25.3% -42.3%  
ROE %  -18.0% -21.9% -24.5% -29.3% -67.3%  

Solidity 
2020
2020/7
2021
2021/7
2022
2022/7
2023
2023/7
2024
2024/7
Equity ratio %  100.0% 100.0% 100.0% 100.0% 100.0%  
Relative indebtedness %  0.0% 0.0% 0.0% 0.0% 0.0%  
Relative net indebtedness %  1,133.1% 561.7% 458.2% 361.9% 106.1%  
Net int. bear. debt to EBITDA, %  1,133.1% 561.7% 458.2% 361.9% 106.1%  
Gearing %  0.0% 0.0% 0.0% 0.0% 0.0%  
Net interest  0 0 0 0 0  
Financing costs %  0.0% 0.0% 0.0% 0.0% 0.0%  

Liquidity 
2020
2020/7
2021
2021/7
2022
2022/7
2023
2023/7
2024
2024/7
Quick Ratio  0.0 0.0 0.0 0.0 0.0  
Current Ratio  0.0 0.0 0.0 0.0 0.0  
Cash and cash equivalent  44.0 36.8 29.4 21.8 8.2  

Capital use efficiency 
2020
2020/7
2021
2021/7
2022
2022/7
2023
2023/7
2024
2024/7
Trade debtors turnover (days)  -0.0 -0.0 -0.0 -0.0 -0.0  
Trade creditors turnover (days)  0.0 0.0 0.0 0.0 0.0  
Current assets / Net sales %  -1,133.1% -561.7% -458.2% -361.9% -106.1%  
Net working capital  44.0 36.8 29.4 21.8 8.2  
Net working capital %  -1,133.1% -561.7% -458.2% -361.9% -106.1%  

Employee efficiency 
2020
2020/7
2021
2021/7
2022
2022/7
2023
2023/7
2024
2024/7
Net sales / employee  0 0 0 0 0  
Added value / employee  0 0 0 0 0  
Employee expenses / employee  0 0 0 0 0  
EBITDA / employee  0 0 0 0 0  
EBIT / employee  0 0 0 0 0  
Net earnings / employee  0 0 0 0 0